Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,813 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Elevated TSH Level, TgAb, and Prior Use of Ramucirumab or TKIs as Risk Factors for Thyroid Dysfunction in PD-L1 Blockade.
Kobayashi T, Iwama S, Yamagami A, Yasuda Y, Okuji T, Ito M, Zhou X, Ando M, Onoue T, Miyata T, Sugiyama M, Hagiwara D, Suga H, Banno R, Hase T, Morise M, Ito T, Kikumori T, Inoue M, Ando Y, Masuda N, Kawashima H, Hashimoto N, Arima H. Kobayashi T, et al. Among authors: ando y, ando m. J Clin Endocrinol Metab. 2022 Sep 28;107(10):e4115-e4123. doi: 10.1210/clinem/dgac467. J Clin Endocrinol Metab. 2022. PMID: 35918067
The feasibility study of docetaxel in patients with anaplastic thyroid cancer.
Kawada K, Kitagawa K, Kamei S, Inada M, Mitsuma A, Sawaki M, Kikumori T, Fujimoto Y, Arima H, Imai T, Ando Y. Kawada K, et al. Among authors: ando y. Jpn J Clin Oncol. 2010 Jun;40(6):596-9. doi: 10.1093/jjco/hyq025. Epub 2010 Mar 3. Jpn J Clin Oncol. 2010. PMID: 20200039 Clinical Trial.
Feasibility of dose-dense epirubicin and cyclophosphamide with subcutaneous pegfilgrastim 3.6 mg support: a single-center prospective study in Japan.
Morita S, Kikumori T, Tsunoda N, Inaishi T, Adachi Y, Ota A, Shibata M, Matsuoka A, Nakanishi K, Takeuchi D, Mizutani T, Shimokata T, Hayashi H, Maeda O, Ando Y. Morita S, et al. Among authors: ando y. Int J Clin Oncol. 2018 Feb;23(1):195-200. doi: 10.1007/s10147-017-1177-z. Epub 2017 Aug 8. Int J Clin Oncol. 2018. PMID: 28791509 Clinical Trial.
Patients With Antithyroid Antibodies Are Prone To Develop Destructive Thyroiditis by Nivolumab: A Prospective Study.
Kobayashi T, Iwama S, Yasuda Y, Okada N, Tsunekawa T, Onoue T, Takagi H, Hagiwara D, Ito Y, Morishita Y, Goto M, Suga H, Banno R, Yokota K, Hase T, Morise M, Hashimoto N, Ando M, Kiyoi H, Gotoh M, Ando Y, Akiyama M, Hasegawa Y, Arima H. Kobayashi T, et al. Among authors: ando y, ando m. J Endocr Soc. 2018 Feb 6;2(3):241-251. doi: 10.1210/js.2017-00432. eCollection 2018 Mar 1. J Endocr Soc. 2018. PMID: 29600292 Free PMC article.
Clinical value of serum bone resorption markers for predicting clinical outcomes after use of bone modifying agents in metastatic bone tumors: A prospective cohort study.
Urakawa H, Ando Y, Hase T, Kikumori T, Arai E, Maeda O, Mitsuma A, Sugishita M, Shimokata T, Ikuta K, Ishiguro N, Nishida Y. Urakawa H, et al. Among authors: ando y. Int J Cancer. 2020 Jun 15;146(12):3504-3515. doi: 10.1002/ijc.32836. Epub 2019 Dec 28. Int J Cancer. 2020. PMID: 31846063
2,813 results